lipoxin a4 has been researched along with ticagrelor in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
Birnbaum, GD; Birnbaum, I; Birnbaum, Y; Nylander, S; Ye, Y | 1 |
2 other study(ies) available for lipoxin a4 and ticagrelor
Article | Year |
---|---|
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine.
Topics: Adenosine; Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Cardiotonic Agents; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Drug Synergism; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Interleukin-6; Lipoxins; Male; Myocardial Reperfusion Injury; Myocardium; NLR Family, Pyrin Domain-Containing 3 Protein; Obesity; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats, Zucker; RNA, Messenger; Rosuvastatin Calcium; Ticagrelor | 2016 |